Physician profile
Christopher J Devine
NPI 1205838562
$2,395.85
in general payments reported to CMS, 2019-2025
21 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $153 · 2021: $268 · 2022: $126 · 2023: $191 · 2024: $346 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.43 |
| Travel and Lodging | $315.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $605.14 | 2025 | |
| Genentech USA, INC. | $306.17 | 2022-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $281.79 | 2019-2021 | |
| Alimera Sciences, INC. | $249.24 | 2019-2021 | |
| Allergan, INC. | $196.37 | 2019-2021 | |
| Abbvie INC. | $188.78 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $161.53 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $122.75 | 2020-2024 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.84 | 2019 | |
| Biogen, INC. | $65.04 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $43.85 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $43.38 | 2024 | Veritas Vision System |
| Bausch & Lomb Americas INC. | $32.97 | 2022-2023 | Visudyne, Retisert, Xipere |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.